Although the monospecific anti-CD123 mAb talacotuzumab demonstrated a poor efficacy with an important toxicity profile in MDS, recent clinical trials assessing CD123 target therapy are showing positive indications for safety and efficacy, despite being limited by low patient numbers [91]. This evidence concerns the gene IL3RA and myelodysplastic syndrome.